On 24th June 2020 the UK Supreme Court handed down their judgement addressing the question of breadth of claim and sufficiency. Although the decision is well written, its background is in biotechnology which is likely to dissuade a lot of people from reading it and/or understanding its broader implications. So with this in mind, here’s my attempt to explain Regeneron v Kymab sufficiency using … TELEPORTATION.
At the time of writing, over one hundred and eighteen thousand cases of novel coronavirus (Covid-19) have been confirmed worldwide and this number is expected to rise significantly. In response to the outbreak, pharmaceutical companies and research organisations are racing to develop new vaccines and repurposing existing anti-viral drugs.